Status:
NOT_YET_RECRUITING
Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib
Lead Sponsor:
Duke University
Collaborating Sponsors:
Pfizer
Conditions:
HER2+ Metastatic Breast Cancer (MBC)
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program...
Eligibility Criteria
Inclusion
- female (sex assigned at birth);
- ≥18 years of age at enrollment;
- diagnosed with HER2+ metastatic breast cancer (mBC);
- receiving treatment with tucatinib combined with capecitabine and trastuzumab;
- able to speak and read English
Exclusion
- visual or hearing impairment;
- severe cognitive impairment;
- severe mental illness interfering with ability to participate
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06983691
Start Date
January 1 2026
End Date
October 1 2026
Last Update
May 21 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.